该研究为肾癌精准治疗提供新思路，强烈推荐科研读者阅读。 首都医科大学的研究人员 Haibo Wang、Yibin Chen 等人在《Cell Death and Disease》期刊上发表了题为 “MAGI3 enhances sensitivity to sunitinib in renal cell carcinoma by suppressing the MAS/ERK axis and ...

Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-α as first-line treatment for patients with metastatic renal-cell carcinoma.

Such a head-to-head trial was conducted by GlaxoSmithKline to compare their tyrosine kinase inhibitor, pazopanib, to another tyrosine kinase inhibitor, sunitinib, in 1110 patients with metastatic ...

Five-year results from a trial examining Exelixis’ Cabometyx as a therapy for previously untreated advanced renal cell carcinoma (RCC) sustaining progression-free (PFS) and overall survival (OS ...